Cited by 421Ferroptosis and cancer prognosisGlioma Diagnosis and TreatmentCancer, Hypoxia, and Metabolism

ATF4 promotes angiogenesis and neuronal cell death and confers ferroptosis in a xCT-dependent manner

Open access
Chen, D, Fan, Z, Rauh, M, Buchfelder, M, Eyupoglu, I Y, Savaskan, N·2017·Oncogene

Abstract

Activating transcription factor 4 (ATF4) is a critical mediator of metabolic and oxidative homeostasis and cell survival. ATF4 is elevated in response to diverse microenvironmental stresses, including starvation, ER stress damages and exposure to toxic factors. Here we show that ATF4 expression fosters the malignancy of primary brain tumors (WHO grade III and IV gliomas) and increases proliferation and tumor angiogenesis. Hence, ATF4 expression promotes cell migration and anchorage-independent cell growth, whereas siRNA-mediated knockdown of ATF4 attenuates these features of malignancy in human gliomas. Further experiments revealed that ATF4-dependent tumor promoting effects are mediated by transcriptional targeting the glutamate antiporter xCT/SCL7A11 (also known as system Xc - ). Thus, xCT is elevated as a consequence of ATF4 activation. We further found evidence that ATF4-induced proliferation can be attenuated by pharmacological or genetic xCT inhibition and ferroptosis inducers such as sorafenib, erastin and GPx4 inhibitor RSL3. Further, fostered xCT expression promotes cell survival and growth in ATF4 knockdown cells. Moreover, increased xCT levels ameliorate sorafenib and erastin-induced ferroptosis. Conversely, ATF4 knockdown renders cells susceptible for erastin, sorafenib and RSL3-induced ferroptosis. We further identified that ATF4 promotes tumor-mediated neuronal cell death which can be alleviated by xCT inhibition. Moreover, elevated ATF4 expression in gliomas promotes tumor angiogenesis. Noteworthy, ATF4-induced angiogenesis could be diminished by ferroptosis inducers erastin and by GPx4 inhibitor RSL3. Our data provide proof-of-principle evidence that ATF4 fosters proliferation and induces a toxic microenvironmental niche. Furthermore, ATF4 increases tumor angiogenesis and shapes the vascular architecture in a xCT-dependent manner. Thus, inhibition of ATF4 is a valid target for diminishing tumor growth and vasculature via sensitizing tumor cells for ferroptosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/onc.2017.146

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The ability of ATF4 to upregulate system xc− and stabilize GPX4 upon HSPA5 transactivation is causally involved in some models of oncogenesis and chemoresistance to ferroptosis induction.

    “the ability of ATF4 to upregulate system xc− and stabilize GPX4 (upon HSPA5 transactivation) is causally involved in some models of oncogenesis and chemoresistance to ferroptosis induction [580, 599].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Chen, D., Fan, Z., Rauh, M., Buchfelder, M., Eyupoglu, I. Y., & Savaskan, N.
Affiliations
Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
Corresponding author
Savaskan, N
Venue
Oncogene
Published
2017-05-29
Volume
36
Issue
40
Pages
5593-5608
ISSN
  • 0950-9232 (ISSN-L)
  • 1476-5594
OpenAlex
W2617266043
Cited by
421
References
42
Citations by year
2026: 28 · 2025: 46 · 2024: 77 · 2023: 67 · 2022: 84 · 2021: 49 · 2020: 36 · 2019: 20 · 2018: 11 · 2017: 3
FWCI
15.84
Type
journal article
Language
en
Open access
Locations
  • Oncogene (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • Repository for Publications and Research Data (ETH Zurich) (submittedVersion, cc-by-nc-sa)
  • ETH Zürich Research Collection
Funders
  • China Scholarship Council
  • RWTH Aachen University
  • Universitätsklinikum Erlangen
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Ferroptosis and cancer prognosis
  • Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Keywords
ATF4, system xc-, ferroptosis, glioma, tumor angiogenesis, neuronal cell death, GPX4, RSL3, erastin, sorafenib, cell proliferation, cell migration, anchorage-independent growth, tumor microenvironment, transcriptional regulation
MeSH terms
Brain Neoplasms, Glioma, Humans, Iron, Neovascularization, Pathologic, Neurons, Gene Expression Regulation, Neoplastic, Cell Death, Glutamic Acid, Amino Acid Transport System y+, Cell Line, Tumor, Cell Proliferation, Activating Transcription Factor 4

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review